BioCentury | Nov 16, 2015
Regulation

Scaling compassion

...of providing preapproval access, according to David Scheer, president of investment and advisory services company Scheer & Co...
...New York, N.Y. Optherion Inc., New Haven, Conn. Parent Project Muscular Dystrophy (PPMD), Hackensack, N.J. Scheer & Co...
BioCentury | Sep 27, 2010
Emerging Company Profile

Axerion: Going beyond NOGO

...NGR decoys and PrP inhibitors Disease focus: Neurology Clinical status: Lead selection Founded: 2009 by Scheer & Co...
BioCentury | Oct 15, 2007
Company News

Optherion board of directors update

...Optherion Inc. New Haven, Conn. Business: Ophthalmic Appointed: David Scheer, president of Scheer & Co. Inc., as chairman...
BioCentury | Oct 10, 2007
Financial News

Optherion raises $37 million

...University of Iowa Carver College of Medicine. David Scheer, president of life sciences advisory firm Scheer & Co...
BioCentury | Jul 31, 2006
Emerging Company Profile

Corporate Profile

...Venture Capital; Johnson & Johnson Development Corp.; Bain Capital; Quaker BioVentures; L Capital Partners; and Scheer & Co...
BioCentury | Jun 27, 2006
Financial News

Tengion raises $50 million

...BioVentures. Existing investors Oak Investment Partners; Johnson & Johnson Development; HealthCap; L Capital Partners; and Scheer & Co...
BioCentury | Aug 8, 2005
Finance

Ebb & Flow

...A round through Oak Investment Partners; Johnson & Johnson Development; HealthCap; L Capital Partners; and Scheer & Co...
BioCentury | Aug 4, 2005
Financial News

Tengion raises $39 million

...A round through Oak Investment Partners; Johnson & Johnson Development; HealthCap; L Capital Partners; and Scheer & Co...
Items per page:
1 - 8 of 8
BioCentury | Nov 16, 2015
Regulation

Scaling compassion

...of providing preapproval access, according to David Scheer, president of investment and advisory services company Scheer & Co...
...New York, N.Y. Optherion Inc., New Haven, Conn. Parent Project Muscular Dystrophy (PPMD), Hackensack, N.J. Scheer & Co...
BioCentury | Sep 27, 2010
Emerging Company Profile

Axerion: Going beyond NOGO

...NGR decoys and PrP inhibitors Disease focus: Neurology Clinical status: Lead selection Founded: 2009 by Scheer & Co...
BioCentury | Oct 15, 2007
Company News

Optherion board of directors update

...Optherion Inc. New Haven, Conn. Business: Ophthalmic Appointed: David Scheer, president of Scheer & Co. Inc., as chairman...
BioCentury | Oct 10, 2007
Financial News

Optherion raises $37 million

...University of Iowa Carver College of Medicine. David Scheer, president of life sciences advisory firm Scheer & Co...
BioCentury | Jul 31, 2006
Emerging Company Profile

Corporate Profile

...Venture Capital; Johnson & Johnson Development Corp.; Bain Capital; Quaker BioVentures; L Capital Partners; and Scheer & Co...
BioCentury | Jun 27, 2006
Financial News

Tengion raises $50 million

...BioVentures. Existing investors Oak Investment Partners; Johnson & Johnson Development; HealthCap; L Capital Partners; and Scheer & Co...
BioCentury | Aug 8, 2005
Finance

Ebb & Flow

...A round through Oak Investment Partners; Johnson & Johnson Development; HealthCap; L Capital Partners; and Scheer & Co...
BioCentury | Aug 4, 2005
Financial News

Tengion raises $39 million

...A round through Oak Investment Partners; Johnson & Johnson Development; HealthCap; L Capital Partners; and Scheer & Co...
Items per page:
1 - 8 of 8